Graham Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Graham Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,606	Closed	-$871K	–	1377
2026 Q1	$871K	Buy	4,606 +3,392	+279%	+$593K	0.02%	474
2025 Q4	$206K	Buy	+1,214	New	+$186K	﹤0.01%	1029
2024 Q1	–	Sell	-5,310	Closed	-$653K	–	1183
2023 Q4	$653K	Sell	5,310 -4,109	-44%	-$513K	0.01%	509
2023 Q3	$1.22M	Buy	+9,419	New	+$1.26M	0.03%	307
2023 Q2	–	Sell	-1,783	Closed	-$261K	–	1133
2023 Q1	$261K	Buy	+1,783	New	+$264K	0.01%	906
2022 Q2	–	Sell	-3,170	Closed	-$493K	–	1130
2022 Q1	$493K	Buy	+3,170	New	+$460K	0.02%	557

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Graham Capital Management's JAZZ Position: Q2 2026 in Review

Graham Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 4,606 shares — an estimated $871K sold.

Graham Capital Management first reported a position in JAZZ in Q1 2022 and held it in 6 quarters. The position peaked at $1.22M in Q3 2023. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Graham Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 4,606 Jazz Pharmaceuticals shares in Q2 2026, an estimated $871K.
Graham Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Graham Capital Management's Jazz Pharmaceuticals position peaked at $1.22M in Q3 2023.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.